KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Consolidated Net Income (2016 - 2025)

Pfizer (PFE) has disclosed Consolidated Net Income for 17 consecutive years, with $25.0 million as the latest value for Q2 2025.

  • Quarterly Consolidated Net Income rose 47.06% to $25.0 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $25.0 million through Dec 2025, up 525.0% year-over-year, with the annual reading at $25.0 million for FY2025, 127.27% up from the prior year.
  • Consolidated Net Income for Q2 2025 was $25.0 million at Pfizer, up from -$8.0 million in the prior quarter.
  • The five-year high for Consolidated Net Income was $34.0 million in Q3 2022, with the low at -$236.0 million in Q3 2021.
  • Average Consolidated Net Income over 5 years is -$16.4 million, with a median of -$3.5 million recorded in 2023.
  • The sharpest move saw Consolidated Net Income tumbled 1000.0% in 2022, then skyrocketed 950.0% in 2024.
  • Over 5 years, Consolidated Net Income stood at -$13.0 million in 2021, then tumbled by 61.54% to -$21.0 million in 2022, then decreased by 23.81% to -$26.0 million in 2023, then surged by 69.23% to -$8.0 million in 2024, then soared by 412.5% to $25.0 million in 2025.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at $25.0 million, -$8.0 million, and $17.0 million for Q2 2025, Q3 2024, and Q2 2024 respectively.